All In Biotech

Drug Trial Radar · NCT02028065

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

382

Actual

Start

Jan 3, 2014

Primary completion

Jul 1, 2014

Study completion Jul 1, 2014

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the potential for hypersensitivity symptoms upon repeat exposure to sugammadex. Healthy participants will be randomized to one of three treatment arms: sugammadex 4 mg/kg, sugammadex 16 mg/kg or placebo. Participants will receive 3 single intravenous (IV) doses of their randomized treatment, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3. Participants will be confined at the study center from the day before each dose until completion of the 24-hour post dose assessments.

Conditions

  • Hypersensitivity
  • Anaphylaxis

Interventions

  • SugammadexDrug

    Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds

  • PlaceboDrug

    Placebo administered as a single IV bolus over 10 seconds

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adjudicated Symptoms of HypersensitivityTime frame: Up to approximately 28 days after last dose (approximately 14 weeks)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.